Does pioglitazone administration improve cardiac function in pubertal patients with cyanotic congenital heart disease?
Targeting insulin resistance with pioglitazone may improve cardiac function in pubertal patients with cyanotic congenital heart disease by restoring HIF-1α-mediated metabolic adaptation.
In patients with CCHD, maladaptation of cardiac metabolism occurred during puberty, along with impaired cardiac function. HIF-1α was identified as the key regulator of cardiac metabolic adaptation in animals exposed to CH, and pubertal insulin resistance could suppress its expression. Pioglitazone administration during puberty might help improve cardiac function in patients with CCHD.
Liu et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: